Searchable abstracts of presentations at key conferences in endocrinology

ea0007p57 | Diabetes, metabolism and cardiovascular | BES2004

Protective effects of phytoestrogens against oxidative stress in human endothelial cells

Zhong W , Adams I , Adams R , Atkin S

Background Phytoestrogens are a group of biologically active plant substances with chemical structures similar to that of endogenous estrogen. Their beneficial effects on cardiovascular protection have been indicated by the relatively lower incidence of cardiovascular diseases in people with higher phytoestrogen consumption. Recent studies show that they have anti-oxidative properties, which have not been studied in human endothelial cells under different glucose conditions.</...

ea0005p146 | Endocrine Tumours and Neoplasia | BES2003

Expression of somatostatin receptors in proliferating and quiescent endothelial cells

Adams R , Adams I , Atkin S

Somatostatin (sst) modulates exocrine and endocrine secretions, cellular proliferation and apoptosis, via a series of 5 G-protein linked transmembrane receptors (sstrs 1-5). Sstrs 2 and 5 have been reported on vasculature but their role remains obscure. Here, we report the expression of sstrs in endothelial cells in vitro, during both proliferative and quiescent states to determine whether these receptors may change dynamically. Endothelial cells were harvested from ten...

ea0007p120 | Endocrine tumours and neoplasia | BES2004

BIM-23244, a somatostatin analogue with high affinity for somatostatin receptors 2 and 5, inhibits endothelial proliferation in vitro

Adams R , Adams I , Zhong W , Lindow S , Atkin S

Somatostatin (SST) modulates exocrine and endocrine secretion, proliferation and apoptosis, via 5 transmembrane receptors (SSTRs 1 to 5), which predominantly signal through inhibitory G proteins. Stable analogs such as Lanreotide and Octreotide have been developed for use in clinical practice. Both have high affinity for SSTR 2, and moderate affinity for SSTR 5. Octreotide has been shown to inhibit endothelial proliferation, probably via SSTR 2, which is expressed by prolifera...

ea0003p264 | Steroids | BES2002

Cortisone reductase (11 beta-hydroxysteroid dehydrogenase type 1) deficiency presenting with features of late onset congenital adrenal hyperplasia

Laing I , Adams J , Wood P , Taylor N , Ray D

A South Asian woman aged 44 years presented with longstanding hirsutism. Her periods had always been regular and she had two children. She had been treated with spironolactone and Dianette without clinical benefit and the hirsutism was managed cosmetically. Investigations showed a high serum testosterone of 6.1 nmol/l ( 1-3nmol/l) and androstenedione 25nmol/l (2-10nmol/l). Serum sex hormone binding globulin was elevated at 96 nmol/l (23-85nmol/l), with normal DHEA sulphate, 4....

ea0007p185 | Reproduction | BES2004

The expression of somatostatin receptors in human granulosa cells

Adams I , Staunton B , Gilson J , Adams R , Robinson J , Atkin S

BackgroundSomatostatin (sst) acts via a series of 5 G-coupled receptors (sstr1-5) which control exocrine and endocrine secretions and also regulate cellular proliferation and apoptosis in many parts of the body. Recent experimental data suggests that sst plays a roles in ovarian function and the synthetic sstr agonists octreotide has been used in the treatment of polycystic ovarian syndrome. We have investigated the expression of somatostatin receptors (...

ea0005oc3 | Reproduction and Development | BES2003

Lipocortin-1 is modulated by glucocorticoids in the human endometrium

Taylor A , Bedford K , Robinson J , Richmond I , Maguiness S , Adams I , Atkin S

Lipocortin 1 (LC1) is a well-characterized anti-inflammatory, -anti mitotic and anti-proliferative member of a structurally related family of Ca2+ and phospholipid-binding proteins. LC1 is readily detectable in the neuroendocrine system by Western blot analysis, ELISA, and immunohistochemistry (1). In these tissues, glucocorticoids regulate both the expression and subcellular distribution of LC1. Other studies have also demonstrated the presence of LC1 in endometrium tissue th...

ea0005p150 | Endocrine Tumours and Neoplasia | BES2003

Expression of vascular endothelial growth factor and its receptors in human anterior pituitary adenomas

Adams I , Henderson R , Green V , Foy P , Macfarlane I , Atkin S

Vascular Endothelial Growth Factor (VEGF) is an important growth factor, simulating the process of angiogenesis which is required for tumour progression. It mainly acts through 2 receptors VEGF-R1 and VEGF-R2. Whilst the presence of VEGF has been shown in pituitary adenomas, no study has undertaken the quantification of the expression of VEGF121, VEGF165, VEGF-R1 and VEGF-R2, and whether their expression may correlate.METHODS. We have used the technique of quantitative RT-...

ea0003p239 | Signalling | BES2002

Dexamethasone blocks mitochondrial targeting-induced apoptosis

Newton C , Bilko D , Adams I , Ran J , Green V , Atkin S

The release of cytochrome c from mitochondria is often the trigger for the nuclear and cytoplasmic changes that characterise apoptotic cell death. Previously, we have shown that vascular endothelial cells of the line, EA.hy 926, undergo apoptosis in response to TNFalpha, camptothecin and oxidants and that this is blocked by the glucocorticoid, dexamethasone (Dex). As a tool to determine where in the apoptotic pathway Dex acts to block the apoptotic process, we have developed a...